腹腔热灌注联合静脉化疗在进展期胃癌术后患者中的应用效果  

Application Effect of Intraperitoneal Hyperthermic Perfusion Combined with Intravenous Chemotherapy in Patients with Advanced Gastric Cancer after Operation

作　　者：吴盛喜[1] 李绪渊[2] 杜泽森[2] WU Sheng-xi;LI Xu-yuan;DU Ze-sen(Department of Radiotherapy,Shantou Central Hospital,Shantou,Guangdong Province,515041 China;Department of Oncology,Shantou Central Hospital,Shantou,Guangdong Province,515041 China)

机构地区：[1]汕头市中心医院放疗科,广东汕头515041 [2]汕头市中心医院肿瘤外科,广东汕头515041

出　　处：《中外医疗》2021年第6期38-40,共3页China & Foreign Medical Treatment

摘　　要：目的探讨腹腔热灌注联合静脉化疗在进展期胃癌术后患者中的应用效果。方法简单随机选择2013年9月—2017年12月该院收治的50例进展期胃癌患者随机分为观察组和对照组,每组25例。两组患者均接受同样的静脉化疗方案,观察组在此基础上给予腹腔热灌注化疗。比较两组临床疗效、治疗前后免疫功能变化和预后情况。结果观察组治疗总有效率大于对照组(60.00%vs 32.00%),差异有统计学意义(χ^(2)=3.945,P=0.047);治疗后两组CD3+、CD4+、CD4+/CD8+水平均显著升高,CD8+水平显著降低,组间比较差异有统计学意义(P<0.05)。观察组术后1年(92.00%)和术后2年生存率(64.00%)均高于对照组(68.00%,36.00%),差异有统计学意义(χ^(2)=4.500,P=0.034;χ^(2)=3.920,P=0.048),术后1年复发率(4.00%)低于对照组(24.00%),差异有统计学意义(χ^(2)=4.153,P=0.042),平均生存时间(36.13±3.26)月长于对照组(30.14±4.95)月,组间比较差异有统计学意义(t=5.053,P<0.001);两组术后2年复发率(24.00%vs 44.00%)比较差异无统计学意义(χ^(2)=2.228,P=0.136)。结论腹腔热灌注化疗治疗进展期胃癌疗效确切,能有效改善患者免疫功能和预后。Objective To investigate the effect of intraperitoneal hyperthermic perfusion combined with intravenous chemotherapy in patients with advanced gastric cancer after surgery.Methods Simply randomly select Fifty patients with advanced gastric cancer admitted to the hospital from September 2013 to December 2017 were randomly divided into observation group and control group,with 25 cases in each group.Both groups of patients received the same intravenous chemotherapy regimen,and the observation group was given intraperitoneal hyperthermic perfusion chemotherapy on this basis.The clinical efficacy,changes in immune function before and after treatment and prognosis were compared between the two groups.Results The total effective rate of treatment in the observation group was greater than that in the control group(60.00%vs 32.00%),and the difference was statistically significant(χ^(2)=3.945,P=0.047);after treatment,the levels of CD3+,CD4+,CD4+/CD8+ in the two groups increased significantly,and the level of CD8+decreased significantly.The difference was statistically significant(P<0.05).The survival rate of the observation group for one year(92.00%)and two years(64.00%)was higher than that of the control group(68.00%,36.00%),and the difference was statistically significant(χ^(2)=4.500,P=0.034;χ^(2)=3.920,P=0.048).The one-year postoperative recurrence rate(4.00%)was lower than that of the control group(24.00%),and the difference was statistically significant(χ^(2)=4.153,P=0.042),and the average survival time(36.13±3.26)months was longer than that of the control group(30.14±4.95)months.The difference between the groups was significant statistically(t=5.053,P<0.001);there was no statistically significant difference in the two-year recurrence rate(24.00%vs 44.00%)between the two groups(χ^(2)=2.228,P=0.136).Conclusion Hyperthermic intraperitoneal chemotherapy is effective in treating advanced gastric cancer and can effectively improve the immune function and prognosis of patients.

关 键 词：腹腔热灌注化疗 进展期胃癌患者 免疫功能 预后 

分 类 号：R735.2[医药卫生—肿瘤]